RhoA and its downstream effector Rho-associated coiled-coil-forming kinase (ROCK) are known regulators of the formation of actin cytoskeleton in cells. Actin cytoskeleton is involved in paramyxovirus infection; we, therefore, examined the effect of ROCK inhibition on measles virus (MV) cytopathic effect and replication. Treatment with the ROCK inhibitor, Y27632, significantly increased syncytia size in tumor cell lines following MV infection, associated with cytoskeleton disruption as demonstrated by actin staining. Treatment of prostate cancer, breast cancer and glioblastoma tumor cell lines with Y27632 following MV infection resulted in increased cytopathic effect, as assessed by trypan blue exclusion assays. In addition, there was a significant increase in viral proliferation by at least one log or more as tested in one-step viral growth curves. Increased viral replication was also observed in athymic nude mice bearing MDA-MB-231 xenografts following combination treatment with MV and Y27632. In summary, inhibition of the ROCK kinase by Y27632 enhanced the oncolytic effect of MV and viral proliferation; this approach merits further translational investigation.
INTRODUCTION
Virotherapy represents an attractive new option in the treatment of malignancy. Measles virus (MV) is a negative-strand RNA virus, and attenuated strains derived from the Edmonton vaccine lineage have antitumor activity against multiple cancer types in vitro and in vivo. MV vaccine strains enter cells primary through the CD46 receptor as well as the recently identified receptor Nectin-4, 1-3 as opposed to the SLAM receptor predominantly used by wild type-MV. Infected cells fuse with neighboring cells with the formation of multinucleated syncytia, [4] [5] [6] [7] which can result in significant bystander effect. Cytoskeleton has been shown to be an important determinant in the replication of paramyxoviruses. 8 Although the role of cellular cytoskeleton in MV infection has not been completely elucidated, actin is thought to have a role in virion maturation and release, [9] [10] [11] [12] as well as in membrane fusion. 13 RhoA belongs to the family of GTPases and it has a crucial role in multiple cellular processes, including cytoskeleton regulation, cell adhesion and migration. 14, 15 Rho-associated coiled-coil-forming kinases (ROCK) and mDia are downstream effectors of Rho. 14, [16] [17] [18] [19] ROCK is a serine/threonine kinase and has been shown to phosphorylate the myosin-binding subunit of myosin phosphatase as well as myosin light chain. These actions result in increased myosin phosphorylation/crosslinking of actin cytoskeleton and increased contractility. 20, 21 Rho/ROCK has been implicated in cell migration through its effects on integrins and cell adhesion. 22, 23 RhoA has also been shown to contribute to malignant transformation. 24 Another Rho isoform, RhoC, has been associated with increased metastatic potential. 25, 26 We hypothesized that since the regulation of cytoskeleton has an important role in MV replication, inhibition of ROCK can lead to enhancement of the efficacy of MV virotherapy. We showed that by inhibiting ROCK we increase cell fusogenicity after infection with MV, with increased cell killing and generation of higher virus titers in vitro. We also confirmed increased viral replication in vivo in mice treated with the MV/ROCK inhibitor combination.
MATERIALS AND METHODS Viruses
The attenuated MV Edmonston vaccine strain was used as a platform for the generation of recombinant MV constructs. Recombinant MVs encoding the human lambda immunoglobulin chain (MV-lambda) 27 and the enhanced green-fluorescent marker protein (MV-GFP) 28 were constructed as previously described. The viruses were propagated in Vero cells and titrated as previously described. 29, 30 Cell lines VERO (African green monkey) cell line and human cancer cell lines DU-145 (prostate cancer), U251 (glioma) and MDA-MB-231 (breast cancer) were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). All cell lines were grown at 37 1C in media recommended by ATCC in a humidified atmosphere of 5% CO 2 . Media contained 100 U ml
penicillin-streptomycin and were supplemented with 10% heat-inactivated fetal bovine serum.
Assessment of MV replication in cancer cell lines DU-145, U251 and MDA-MB-231 cells were plated in six-well plates at a density of 5 Â 10 5 cells per well. Twenty-four hours after seeding, the cells were infected with MV-GFP at an MOI of 0.1 in 0.5-1.0 ml of Opti-MEM for 2-4 h at 37 1C. At the end of the incubation period, the virus was removed and the cells were treated with Y27632 (Sigma-Aldrich, St Louis, MO, USA) dissolved in dimethyl sulfoxide at concentrations of 150 mm, 100 mm and 25 mm for the MDA-MB-231, DU145 and U251 cell lines respectively; An equivalent amount of dimethyl sulfoxide was added to the control wells in their standard medium. Cells were harvested at specified time points and MV-GFP was released by two cycles of freezing/thawing. The viral titer at each well was determined by 50% end point dilution assay (TCID 50 ) on Vero cells in a 96-well plate. 31 Results are presented as the means of three independent experiments±s.e.m.
Assessment of syncytia size
Cancer cells (MDA-MB-231 and DU-145) were infected with MV-GFP at MOI 0.01 and then treated with Y27632 as described above. Cells were fixed with formaldehyde and crystal violet-stained at 72 h post MV-GFP infection. Photographs were taken from four peripheral quadrants and the center of two wells per time point. Quantitation of the syncytial surface per plate was performed using NIH Image J software (NIH, USA, version 1.46) and results were expressed as the number of pixels per syncytia. 32 Assessment of the cytopathic effect in vitro U251 and MDA-MB-231 cells were plated in six-well plates at a density of 5 Â 10 5 cells per well. Twenty-four hours after seeding, the cells were infected with MV-GFP at a MOI of 0.1 in 0.5-1.0 ml of Opti-MEM for 2 h at 37 1C. At the end of the incubation period, the virus was removed and the cells were treated with Y27632 at 75-150 mM; equivalent amount of dimethyl sulfoxide was added to control wells in their standard medium. 
Actin staining
Tumor cells were plated on tissue culture microscope slides. Y27632 was added at specified time points and all cells were incubated for 48 h. Cells were then stained using Invitrogen Alexa Fluor 488 Phalloidin Conjugate (Invitrogen, Carlsbad, CA) as per the manufacturer's instructions. Briefly, cells were fixed in 3.7% formaldehyde solution and then permeabilized with 0.1% Triton X-100 solution. Afterwards they were incubated with Alexa Fluor 488 Phalloidin Conjugate (Invitrogen) and visualized on microscope.
Enzyme-linked immunosorbent assay (ELISA) for detection of human lambda immunoglobulin Cells were infected with MV-Lambda and then treated with Y27632 in a similar manner as described above. At specified time point, 100 ml of media was removed for the analysis. Quantitative ELISA for human lambda immunoglobulin was performed using an ELISA kit (Bethyl Laboratories, Montgomery, TX, USA) according to the manufacturer's protocol.
To assess the impact of inhibition of fusion, FIP (Z-D-Phe-L-Phe-Gly-OH (Bachem, Torrance, CA, USA)) (20 mg ml À 1 ) was added to select wells after incubation with the MV to inhibit F-protein function and block syncytia formation. ELISA to detect the human lambda light chain was performed as described above.
SDS-PAGE immunoblotting
Supernatants and cell lysates were prepared from tumor MV-GFP infected cells (MOI of 0.01) with or without the addition of Y27632. Uninfected cells were used as controls. Proteins were electrophoresed in 12.5% polyacrylamide gels using the Criterion electrophoresis system (Bio-Rad, Hercules, CA, USA). For immunoblotting, SDS-PAGE-fractionated proteins were blotted on polyvinylidene difluoride membranes (Bio-Rad) using a semi-dry transfer system (Bio-Rad). Five to ten percent of non-fat dry milk (Bio-Rad) in PBS/T was used for blocking. Membranes were incubated with supernatant dilutions of Anti-N mouse antibody developed in our laboratory (publication pending) overnight at 4 1C. Rabbit mouse-specific polyvalent immunoglobulin (G, A, M) HRPO conjugate (diluted 1:2000 in 5% dry milk in PBS/T) was used as the secondary antibody (Pierce, Rockford, IL, USA). Specific protein bands were visualized using chemiluminescent reagent (Pierce).
In vivo experiments
All animal studies were approved by the Mayo Foundation Institutional Animal Care and Use Committee. Mice were maintained in the animal facilities of Mayo Clinic, Rochester, MN, USA.
Subcutaneous MDA-MB-231 tumor model
Xenografts derived from the MDA-MB-231 cell line were established into the right flanks of 6-to 8-week-old female BALB/c nude mice by subcutaneous injection of 5 Â 10 6 cells suspended in 0.1 ml PBS and 0.1 ml of BD Matrigel basement membrane matrix (BD Biosciences, Bedford, MA, USA). The mice were examined daily for tumor growth. Tumor volume was measured with calipers twice weekly and calculated using the formula: volume ¼ [(smallest diameter) 2 Â (largest diameter)]/2. Once all tumors were 4500 mm 3 , mice were randomly divided into two groups (n ¼ 3). All tumors received injection with 1.5 Â 10 6 TCID 50 MVLambda. Subsequently, the mice were treated either with 100 ml of PBS or Y27632 dissolved in PBS at 10 mg kg À 1 through intra-abdominal injection twice daily. On day 5, mice were euthanized and blood was collected. Serum was analyzed with quantitative ELISA for lambda detection as described above.
Statistical analysis
Statistical comparisons were carried out using the Student's t-test. The data obtained are expressed as mean±s.d. P-values of o0.05 were considered statistically significant.
RESULTS

Treatment with Y27632 causes increased MV-induced syncytia in vitro
Initially, we examined the ability of the Y27632 to inhibit cellular proliferation. Concentrations with minimal effect on cellular proliferation were used in subsequent experiments in order to evaluate its effect on MV replication (data not shown). Next, we determined the optimal sequence of MV infection/Y27632 treatment. We tested different sequences of Y27632 ranging from 24 h prior to 24 h post infection and determined that the best effect was observed when cells were treated with Y27632 up to 6 h post infection. Increased size of MV-induced syncytia was observed across different tumor types, with representative results in MDA-MB-231 breast cancer cells shown in Figure 1a . We used the NIH ImageJ software to quantify the size of the syncytia in MDA-MB-231 and DU-145 cell lines. Treatment with Y27632 significantly increased the syncytia size of MV-infected cells in both MDA-MB-231 and DU-145 cell lines (Figures 1b and c) .
Treatment with Y27632 results in disruption of the actin cytoskeleton We investigated whether Y27632 at concentrations that increase syncytia size has an effect on the actin cytoskeleton. As shown in Figure 2 , treatment with Y27632 concentrations that affected syncytia formation over a period ranging from 24 to 48 h had a significant effect on the actin cytoskeleton and induced a distinctive phenotype in MDA-MB-231 and DU-145 cells, with disruption of the actin cytoskeleton and increase in staining for actin filaments.
Treatment with Y27632 causes increased MV-induced cytopathic effect in vitro Next, we explored the question of whether increase in syncytia size is associated with increased cell death following treatment with MV in combination with Y27632. We explored this question in MDA-MB-231 (breast cancer) and U251 (glioma) cell lines. Cells were infected with MV at a multiplicity of infection (MOI) of 0.1 with concentrations of Y27632 that were previously determined to have minimal effect on cell proliferation. In both cell lines, the combination therapy was superior to either treatment alone, as determined by trypan blue exclusion assays (Figure 3a) . This effect was dependent on the concentration of Y27632 as shown in Figure 3b . On day 6 following infection, 50% of cells were viable after treatment with MV alone versus 43% cells being viable (P ¼ 0.0158) after MV treatment in combination with 75 mM Y27632, and 23% after MV treatment in combination with 150 mM of Y27632 (P ¼ 0.0017). Y27632 single-agent treatment had minimal impact on cell proliferation at the same concentrations.
Treatment with Y27632 leads to increased MV replication in vitro
In order to examine the effect of Y27632 on MV replication, we determined viral replication in three cell lines (MDA-MB-231, U251 and DU-145) by one-step viral growth curves. As shown in Figure 4a , there was a significant increase in the amount of virus recovered in all three cell lines following combination treatment. As Figure 4b shows, the impact of Y27632 on viral replication was dependent on the concentration of the drug; increasing concentrations of Y27632 resulted in significant increases in MV titers. To confirm these findings we examined levels of viral N protein expression in the infected cells. As Figure 5 demonstrates, there was an increase in nucleocapsid (N) protein in cells treated with Y27632 as compared to cells infected with MV alone. In order to further examine the effect of Y27632 treatment on viral gene expression, an MV strain engineered to express the human lambda light chain was used (MV-Lambda) (Figure 6a) , with levels of lambda light chain serving as a correlate to viral replication. MDA-MB-231 cells treated with Y27632 after infection with MVLambda had a statistically significant increase in lambda production as compared to cells infected with virus alone (Figure 6b ) at 48 h (P ¼ 0.0157) and 72 h (P ¼ 0.0002) after infection. These experiments demonstrate that treatment with Y27632 leads to increased MV replication in vitro in breast, glioma and prostate cancer cell lines.
We also asked the question whether the ability to form syncytia is necessary for the observed effect of Y27632 on viral replication. MDA-MB-231 cells were infected with MV-Lambda and then treated with fusion-inhibitory peptide (FIP) in addition to Y27632. FIP abrogated the ability of the MV to form syncytia and decreased viral replication. As shown in Figure 7 , there was significant decrease in lambda light chain levels in the supernatant of cells treated with FIP/MV-Lambda combination as compared with control cells infected with MV-Lambda alone. Addition of Y27632 did not increase the production of lambda (Figure 7) . Therefore, syncytia formation is necessary for the Y27632 to enhance MV replication.
Y27632 increases viral replication in vivo
The ability of Y27632 to increase viral replication was also tested in vivo in the MDA-MB-231 cell flank mouse tumor model. The flank tumors were injected with one dose of MV-Lambda (2.0 Â 10 6 TCID 50 ). The mice were treated with phosphate-buffered saline (PBS) or Y27632 dissolved in PBS intraperitoneally at a dose of 10 mg kg À 1 twice daily for 5 days. On day 5, blood was obtained from the mice and serum was tested for the levels of human lambda light chain. A statistically significant increase in human lambda levels in mice treated with Y27632 in combination with MV-lambda (P ¼ 0.0462) was detected as compared to mice treated with MV-lambda/PBS (Figure 8 ). There was no observed toxicity in association with the Y27632 therapy.
DISCUSSION
Virotherapy is a novel and highly promising new treatment option for cancer patients. The MV vaccine strains represent a potent oncolytic platform with activity against a variety of solid as well as hematologic malignancies in vitro and in vivo, including glioblastoma, [33] [34] [35] [36] [37] [38] [39] 46 multiple myeloma, mesothelioma, glioblastoma, and head and neck cancer. Promising early clinical activity was observed in ovarian cancer patients 47 while clinical data in other tumor types are maturing. Further increasing the efficacy of measles virotherapy by exploring combination strategies is the translational question that the second-generation of clinical trials will address.
Paramyxoviridae have been shown to interact with cellular actin. [48] [49] [50] Actin alterations have also been associated with the changing of fusogenicity of cells during viral infection. 13 Rho family GTPases are involved in multiple cellular functions, one of which involves actin cytoskeleton regulation. 14, 15 Rac1 has been found to have a role in modulating actin cytoskeleton during viral infection. 51 We, therefore, explored the role of ROCK, the downstream effector of Rho GTPases, in actin cytoskeleton modulation and fusogenicity during MV infection. Y27632 is a specific ROCK inhibitor. 52 Treatment of cancer cells with Y27632 leads to decreased cell mobility and metastatic potential, 16, [53] [54] [55] [56] prevention of malignant transformation, 57 as well as increased apoptosis.
58 Y27632 treatment leads to increased expression of integrins and subsequent overexpression of adhesion molecules. We showed that treatment with Y27632 following measles infection increases syncytia size, which results in higher viral titers and antitumor effect. The mechanism of increased fusogenicity is likely related to the effect of Y27632 on the actin cytoskeleton in cells treated with the MV/Y27632 combination; of note, the cytoskeleton changes induced by Y27632 not only did not adversely affect MV replication but in fact they increased it in a syncytia area-dependent manner.
The Rho/ROCK pathway and its role in human cancer is currently under active investigation. Several mutations of Rho proteins have been identified 59 and they have been found to be overexpressed in different cancer types. 25, 60 Preclinical data indicate antitumor activity of ROCK inhibitors 16 against in breast, 61 melanoma 62 and hepatocellular 63 cancer. As our data suggests, combining this new class of drugs with MV may lead to a synergistic antitumor effect.
In summary, we showed that ROCK inhibition results in increased syncytia formation, and cytopathic effect, as well as increased viral replication of MV in vitro. Enhanced MV replication following combination treatment with a ROCK inhibitor was also observed in a breast cancer animal model. These results contribute to the better understanding of the importance of the Rho/ROCK pathway in measles oncolytic virotherapy and encourage the investigation of future translational application of combining MV strains with ROCK inhibitors or other cytoskeletonmodifying agents. ), they were treated with one intratumoral injection of MV-Lambda 2 Â 10 6 TCID 50 . The experimental group received in addition Y27632 via intraperitoneal injection twice daily at a 10 mg kg À 1 dose for a total of 10 doses, with the control group receiving PBS. On day 5, blood was obtained from the animals and lambda light chain levels were measured in serum.
